Hook & thesis
Rocket Lab has just moved from a fast-growing launch specialist to a vertically integrated satellite-services contender. The company's agreed acquisition of Iridium for $8 billion - $54 per share composed of $27 cash and the remainder in stock - is the catalyst. This is not a bolt-on; it puts Rocket Lab on a path to combine launch, spacecraft manufacturing and a recurring satcom revenue stream.
We are upgrading Rocket Lab to a buy and proposing a mid-term swing trade. The trade banks on the market re-rating the combined company as investors assign durable value to Iridium's subscription-like revenues and Rocket Lab's expanding launch franchise, while the firm's operational execution and backlog provide de-risked revenue visibility.
Why the market should care - business fundamentals
Rocket Lab runs two business lines: Launch Services and Space Systems. Launch Services sells dedicated and rideshare missions while Space Systems designs and manufactures spacecraft and runs on-orbit operations. With the Iridium deal, Rocket Lab adds a global L-band satellite constellation and established service contracts across IoT, aviation, maritime and positioning markets.
Concrete numbers matter. The company reported record Q1 2026 revenue of $200.3 million and carries a backlog topping $2.2 billion. On the balance sheet and valuation front the market already prices high expectations: market capitalization sits roughly at $58.6 billion while enterprise value is about $60.1 billion. Free cash flow is negative -$316.3 million in the latest period, and EPS remains negative, with the last reported diluted EPS around -$0.29.
The strategic logic is straightforward: add Iridium's recurring revenue and service margins to Rocket Lab's native launch growth. That can convert a lumpy launch revenue profile into a steadier, more predictable multi-year free cash flow profile if management successfully integrates operations and retains Iridium customers.
Supporting evidence and what the numbers tell us
- Operational execution: Rocket Lab completed its 12th launch of the year and has a 100% mission success streak for the last 10 dedicated launches for one customer, underscoring reliability as Electron remains the industry's most frequently launched small-lift rocket.
- Backlog and revenue trajectory: $2.2B+ backlog and Q1 2026 revenue of $200.3M indicate meaningful visibility into revenues over the next several quarters as backlog converts.
- Valuation context: at roughly $58.6B market cap versus current trailing revenue, the market prices large growth and durable margins into the equity. Price-to-sales multiples are elevated (historic and trailing ratios show extremely high P/S), reflecting both optimism and risk; the Iridium deal is the key to justify a higher multiple if it delivers recurring cash flows.
- Balance sheet and leverage: debt-to-equity is low by aerospace standards at about 0.02, but free cash flow is negative, and the deal structure (part cash, part stock at $54 per Iridium share) will alter the capital structure and share count — something to watch closely as integration proceeds.
Technical backdrop
Share price trades around $101.35 with a 52-week range of $33.73 to $151.00. Short interest data show days-to-cover sitting around 1.3 on recent settlement dates and elevated short volume on heavy days, which can amplify move magnitude around news flow. Momentum indicators are mixed: the 10-day SMA is near $96.23 while the 20- and 50-day SMAs are higher, suggesting recent consolidation after the May highs.
Valuation framing - why the premium might stick
Rocket Lab commands a valuation that implies the market expects it to become more than a launch company. With market cap roughly $58.6B and enterprise value near $60.1B, the premium requires materially higher revenue and margin visibility than launch alone provides. The Iridium purchase supplies one of the clearest pathways to that outcome - recurring service revenue, cross-selling opportunities for hosted payloads, and the potential to lock customers into Rocket Lab's launch pipeline.
That said, the company is not cheap on classic fundamentals: EPS is negative, FCF is negative, and P/S is extremely elevated by historical standards. For the valuation to normalize upward, investors will need signs of margin expansion or an improving free cash flow profile as Iridium revenues scale post-close.
Catalysts
- Integration milestones for the Iridium acquisition - regulatory approvals, financing finalization, and early synergy announcements.
- Demonstration flight and public milestones for Neutron - successful test flights or progress updates that validate medium-lift capability and revenue potential.
- Backlog conversion - steady cadence of launches converting backlog to recognized revenue over the next quarters.
- Operational scale wins - further high-frequency launches and continued mission success that underpin cost leverage.
- Revenue and margin guidance from combined entity in the next earnings cycle showing tangible improvement.
Trade plan (actionable)
Direction: Long.
Entry: Buy at $101.35 (current market level).
Stop loss: $95.00. Place a hard stop below the 10-day SMA and recent intra-day support to limit downside if sentiment shifts or integration concerns emerge.
Target: $140.00. This target sits below the 52-week high of $151 and assumes positive integration headlines and an improving fundamental story that justifies part of the premium assigned by the market. We view this as a mid-term trade.
Horizon: mid term (45 trading days). This window lets the market digest near-term integration updates, any initial financing or synergy disclosures and a couple of launch confirmations which typically move investor sentiment faster than organic quarterly results. If the trade reaches the target and shows momentum, consider letting a smaller position run toward the $150 area with a tightened trailing stop.
Risk framing - what can go wrong (and a counterargument)
- Integration risk: Combining a manufacturing-and-launch business with a global satcom operator is complex. Systems, culture and regulatory mismatches could delay synergies and dilute near-term returns.
- Funding and dilution: The deal is partly-stock financed. Share issuance and any additional debt to fund cash components can dilute existing holders and pressure the stock if investors view the financing as unfavorable.
- Free cash flow and margins: FCF was negative -$316.3M recently and EPS negative. If Iridium's margins or operating costs are worse than expected, the combined free cash flow profile may not improve fast enough to justify current multiples.
- Competitive pressure from SpaceX: SpaceX's scale and Starlink dynamics are a constant overhang. If SpaceX further integrates down-market services or offers lower-cost launch capacity for Iridium-like traffic, price and margin pressures could emerge.
- Macro and market sentiment: The equity trades at rich multiples - any broad risk-off or rotation away from space/tech names can quickly compress the stock even absent company-specific setbacks.
Counterargument: The skeptic case is straightforward: the stock is priced for perfection, with high multiples and negative cash flow. If Iridium turns out to be a costly integration or fails to produce accretive recurring cash flow, investors will re-price the company sharply lower. That is a plausible outcome and justifies a disciplined stop at $95.
Conclusion and what would change my mind
We are upgrading to a buy and laying out a mid-term swing trade at $101.35 with a $95 stop and a $140 target. The rationale is the transformation of Rocket Lab's business profile from transactional launches to a launch-to-service company with recurring satellite revenue - a combination that can command a higher multiple if executed. The trade balances the upside from integration and backlog conversion with the clear real risks of dilution, execution and cash burn.
What would change my view: a) any material delay or failure in the Neutron program that shifts launch economics; b) an announcement that the Iridium financing materially dilutes existing shareholders beyond current expectations; c) a post-close guidance cut or material miss in backlog conversions. Conversely, faster-than-expected synergy realization, improving free cash flow and clean, low-dilution financing would strengthen the bullish case and justify a higher target.
Trade summary: Buy RKLB at $101.35, stop $95.00, target $140.00. Mid-term horizon - 45 trading days. Upgrade to buy based on Iridium acquisition and execution tailwinds; manage position size against integration and valuation risks.